Nova Eye Medical Limited (ASX:EYE)

Market Cap	34.10M
Revenue (ttm)	26.11M
Net Income (ttm)	-8.56M
Shares Out	284.15M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,940
Average Volume	351,123
Open	0.1200
Previous Close	0.1200
Day's Range	0.1170 - 0.1200
52-Week Range	0.0860 - 0.2950
Beta	0.65
RSI	49.70
Earnings Date	May 26, 2025

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter which offers malleability and manoeuvrability than common nylon alternatives; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2R...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1970
• Employees: 301
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EYE

Financial Performance

In 2024, Nova Eye Medical's revenue was 23.33 million, an increase of 37.00% compared to the previous year's 17.03 million. Losses were -8.79 million, -42.52% less than in 2023.